Emergent BioSolutions Submits Biologics License Application To FDA For Anthrax Immune Globulin Intravenous (Human)

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for Anthrax Immune Globulin Intravenous (Human) [AIGIV] as part of a development contract with the Biomedical Advanced Research and Development Authority (BARDA). AIGIV, which was acquired in the Cangene acquisition completed earlier this year, is being developed as an intravenous therapeutic treatment for inhalation anthrax.

Help employers find you! Check out all the jobs and post your resume.